Kidney Disease Management: Treatment Options by Stage and Etiology
Chronic kidney disease (CKD) affects 15% of US adults. While most CKD is not "curable," progression can be slowed, complications managed, and quality of life preserved through stage-appropriate interventions.
CKD Staging (KDIGO)
| Stage | eGFR (mL/min/1.73m²) | Focus |
| G1 | ≥90 | Normal/high; monitor if kidney damage present |
| G2 | 60-89 | Mildly decreased; risk factor control |
| G3a | 45-59 | Mild-moderate; complication screening |
| G3b | 30-44 | Moderate-severe; nephrology referral |
| G4 | 15-29 | Severe; prepare for KRT |
| G5 | <15 | Kidney failure; KRT initiation |
Conservative Management (All Stages)
Blood Pressure Control
- Target <130/80 (KDIGO/ACC/AHA)
- ACEi/ARB first-line: Renoprotective (reduce intraglomerular pressure, proteinuria)
- Add thiazide (G1-3), loop diuretic (G4-5), CCB, MRA as needed
Glycemic Control (Diabetic Kidney Disease)
- SGLT2 inhibitors: Empagliflozin, dapagliflozin, canagliflozin — renal & CV benefit independent of glucose
- GLP-1 RAs: Semaglutide, dulaglutide — renal benefit
- A1c target individualized (generally <7%, higher if frail/hypoglycemia risk)
Lipid Management
- Statin ± ezetimibe for CVD prevention (CKD = CVD risk equivalent)
Dietary Modifications
- Sodium <2.3 g/day (5 g salt)
- Protein 0.8 g/kg/day (G3-5, non-dialysis); avoid high protein
- Potassium restriction if hyperkalemic (G4-5)
- Phosphate restriction if hyperphosphatemic (G4-5)
- Plant-dominant diet may slow progression
Anemia Management
- Iron repletion (IV preferred in CKD)
- ESAs (epoetin, darbepoetin) if Hb <10 g/dL; target 10-11 g/dL
- HIF-PH inhibitors (roxadustat, vadadustat) — emerging oral alternative
Mineral and Bone Disorder (CKD-MBD)
- Phosphate binders (calcium-based, sevelamer, lanthanum, sucroferric oxyhydroxide)
- Vitamin D analogs (calcitriol, paricalcitol) for secondary hyperparathyroidism
- Calcimimetics (cinacalcet) for refractory SHPT
Kidney Replacement Therapy (KRT) — Stage G5
Hemodialysis
- In-center (3×/week) or home (more frequent, better outcomes)
- Vascular access: AVF > AVG > catheter
Peritoneal Dialysis
- Continuous ambulatory (CAPD) or automated (APD)
- Preserves residual function; more lifestyle flexibility
Kidney Transplant
- Best survival and quality of life
- Living donor preferred (preemptive ideal)
- Deceased donor waitlist: 3-5+ years
Conservative / Palliative Care
- Symptom management without dialysis
- Appropriate for frail, elderly, multi-morbid patients
- Advance care planning essential
Acute Kidney Injury (AKI) — Potentially Reversible
- Prerenal (volume), intrinsic (ATN, GN, AIN), postrenal (obstruction)
- Early recognition, volume optimization, nephrotoxin avoidance, RRT if indicated
- Recovery common but increases long-term CKD risk
Multidisciplinary Care
- Nephrologist, dietitian, pharmacist, social worker, vascular access coordinator
- Patient education: CKD stage, trajectory, options, advance directives
- Early referral (G3b) improves outcomes
CKD management is proactive, not reactive. Slowing progression preserves options and years of life.
Kidney Disease - Related Articles